Micelle/Hydrogel Composite as a “Natural Self-Emulsifying Reversible Hybrid Hydrogel (N’SERH)” Enhances the Oral Bioavailability of Free (Unconjugated) Resveratrol

The poor oral bioavailability, rapid biotransformation to less active metabolites, and fast elimination from systemic circulation have been identified as the major limitations responsible for the clinical insignificance of many drug candidates and phytonutrients. Despite the technological advancements in the nanoformulations of synthetic drugs, there exist many challenges for nutritional therapy, due to the regulatory issues, use of high levels of synthetic emulsifiers and polymers, low stability, low loading levels, mainly liquid state, etc. Herein, we report the characterization and human pharmacokinetics of a natural self-emulsifying hybrid-hydrogel formulation of trans-resveratrol prepared by uniformly impregnating resveratrol micelles into the fenugreek galactomannan hydrogel scaffold to form a water-soluble micelle/hydrogel composite in powder form (RF-20). Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), particle size analysis by dynamic light scattering (DLS), and transmission electron microscopy (TEM) demonstrated the uniform impregnation of resveratrol micelles within the galactomannan hydrogel matrix to form a soluble (average particle size of 172.0 ± 10.4 nm and −21.0 ± 2.5 mV zeta potential) and amorphous powder form with smooth and translucent surface morphology for RF-20, with no chemical alterations. Upon pharmacokinetic studies on healthy human subjects (n = 16) following a randomized, double-blinded, placebo-controlled, 2-arm, 4-sequence crossover design and tandem mass spectrometry (UPLC-ESI-MS/MS), 80 mg of trans-resveratrol from RF-20 provided enhanced free resveratrol bioavailability and pharmacokinetic properties compared to the unformulated resveratrol with 98% purity. The enhancement in bioavailability was more when supplemented in sachet (12.98-fold) form than the capsule (10.48-fold) with improved absorption (Cmax = 50.97 ± 15.82 ng/mL), circulation half-life (t1/2 = 7.01 ± 1.44 h), and sustained delivery (Tmax = 4.71 ± 0.73 h), as compared to the unformulated form (Cmax = 15.07 ± 5.10 ng/mL; t1/2 = 1.58 ± 0.65 h; Tmax = 1.21 ± 0.42 h).

[1]  Dinesh Kumar,et al.  Enhanced absorption of curcuminoids and 3-Acetyl-11-keto-β-boswellic acid from fenugreek galactomannan hydrogel beadlets: A natural approach to the co-delivery of lipophilic phytonutrients , 2021 .

[2]  Mao-Hua Cai,et al.  Design and Development of Hybrid Hydrogels for Biomedical Applications: Recent Trends in Anticancer Drug Delivery and Tissue Engineering , 2021, Frontiers in Bioengineering and Biotechnology.

[3]  C. Sőti,et al.  The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: From antioxidant to epigenetic therapy , 2021, Ageing Research Reviews.

[4]  Nicholas A. Peppas,et al.  Engineering precision nanoparticles for drug delivery , 2020, Nature reviews. Drug discovery.

[5]  A. Rao,et al.  Trans-Resveratrol Oral Bioavailability in Humans Using LipiSperse™ Dispersion Technology , 2020, Pharmaceutics.

[6]  C. Dima,et al.  Bioavailability of nutraceuticals: Role of the food matrix, processing conditions, the gastrointestinal tract, and nanodelivery systems. , 2020, Comprehensive reviews in food science and food safety.

[7]  K. Jadhav,et al.  A Stability Indicating Reversed Phase HPLC Method for Estimation of trans-Resveratrol in Oral Capsules and Nanoliposomes , 2019, Analytical Chemistry Letters.

[8]  F. Caputo,et al.  Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI‐NCL. A step by step approach combining orthogonal measurements with increasing complexity , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[9]  I. Casaburi,et al.  Progress to Improve Oral Bioavailability and Beneficial Effects of Resveratrol , 2019, International journal of molecular sciences.

[10]  Subash C. Gupta,et al.  Health benefits of resveratrol: Evidence from clinical studies , 2019, Medicinal research reviews.

[11]  R. Lamuela-Raventós,et al.  Health Effects of Resveratrol: Results from Human Intervention Trials , 2018, Nutrients.

[12]  K. Wei,et al.  Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy , 2018, Royal Society Open Science.

[13]  J. Pezzuto Resveratrol: Twenty Years of Growth, Development and Controversy , 2018, Biomolecules & therapeutics.

[14]  A. Bosy-Westphal,et al.  The Oral Bioavailability of Trans‐Resveratrol from a Grapevine‐Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization , 2018, Molecular nutrition & food research.

[15]  James R. Smith,et al.  Liposomal Drug Delivery Systems and Anticancer Drugs , 2018, Molecules.

[16]  V. Steenkamp,et al.  Bioavailability of resveratrol : possibilities for enhancement , 2017 .

[17]  Chih-Wei Chang,et al.  Self-Nanoemulsifying Drug Delivery System for Resveratrol: Enhanced Oral Bioavailability and Reduced Physical Fatigue in Rats , 2017, International journal of molecular sciences.

[18]  Xiaodong Ma,et al.  Differential sensitivities of bladder cancer cell lines to resveratol are unrelated to its metabolic profile , 2017, Oncotarget.

[19]  Dimitrios N. Bikiaris,et al.  Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses , 2016, International journal of molecular sciences.

[20]  Peter R C Howe,et al.  Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus , 2016, Nutrients.

[21]  Dinesh Kumar,et al.  Enhanced bioavailability and relative distribution of free (unconjugated) curcuminoids following the oral administration of a food-grade formulation with fenugreek dietary fibre: A randomised double-blind crossover study , 2016 .

[22]  J. Viña,et al.  Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans , 2015, Oxidative medicine and cellular longevity.

[23]  S. K. Bedada,et al.  Effect of Resveratrol on the Pharmacokinetics of Carbamazepine in Healthy Human Volunteers , 2015, Phytotherapy research : PTR.

[24]  Dinesh Kumar,et al.  Improved blood–brain-barrier permeability and tissue distribution following the oral administration of a food-grade formulation of curcumin with fenugreek fibre , 2015 .

[25]  J. Smoliga,et al.  Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution? , 2014, Molecules.

[26]  G. Betageri,et al.  Improved oral delivery of resveratrol using proliposomal formulation: investigation of various factors contributing to prolonged absorption of unmetabolized resveratrol , 2014, Expert opinion on drug delivery.

[27]  K. Brown,et al.  Sulfate Metabolites Provide an Intracellular Pool for Resveratrol Generation and Induce Autophagy with Senescence , 2013, Science Translational Medicine.

[28]  Claude Emond,et al.  Optimization of trans-Resveratrol bioavailability for human therapy. , 2013, Biochimie.

[29]  A. Amri,et al.  Administration of resveratrol: What formulation solutions to bioavailability limitations? , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[30]  T. Walle Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[31]  Neeraj Singhal,et al.  Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects , 2010, Clinical pharmacokinetics.

[32]  R. Lamuela-Raventós,et al.  Matrix effects on the bioavailability of resveratrol in humans , 2010 .

[33]  D. Kennedy,et al.  Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. , 2010, The American journal of clinical nutrition.

[34]  A. Falcão,et al.  Pharmacokinetics of Trans‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects , 2009, Journal of clinical pharmacology.

[35]  A. Falcão,et al.  Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. , 2009, Molecular nutrition & food research.

[36]  M. Miksits,et al.  Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. , 2009, Planta medica.

[37]  C. Porter,et al.  Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.

[38]  V. Somoza,et al.  Metabolism and bioavailability of trans-resveratrol. , 2005, Molecular nutrition & food research.

[39]  A. Heredia,et al.  Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. , 2004, Journal of pharmaceutical sciences.

[40]  H. Esumi,et al.  Pharmacokinetic analysis of factors determining elimination pathways for sulfate and glucuronide metabolites of drugs. I: Studies by in vivo constant infusion , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[41]  R. J. Hintz,et al.  The effect of particle size distribution on dissolution rate and oral absorption , 1989 .

[42]  Dinesh Kumar,et al.  An enhanced bioavailable formulation of curcumin using fenugreek-derived soluble dietary fibre , 2012 .